U.S. Infrastructure Stock News

NYSE:PBI
NYSE:PBICommercial Services

How Investors May Respond To Pitney Bowes (PBI) Highlighted As a Value Play by Zacks

Pitney Bowes was recently highlighted by Zacks with a Strong Buy rating and an A grade for Value, citing its lower Forward P/E and PEG ratios relative to industry averages as indicating potential undervaluation. This renewed analyst attention underscores how Pitney Bowes’ valuation metrics compare favorably with sector peers, potentially reshaping how investors assess its balance between risk and reward. Next, we’ll examine how Pitney Bowes’ Strong Buy rating and value-focused metrics...
NYSE:GHM
NYSE:GHMMachinery

Graham (GHM) Moved, What Is Behind The Latest Attention?

Graham stock moves after contract wins, earnings update and guidance reaffirmation Graham (GHM) stock has been reacting to a cluster of recent company updates, including more than US$43 million in new defense contracts, first quarter fiscal 2027 results, and reaffirmed full year sales guidance. See our latest analysis for Graham. Graham’s recent contract awards, earnings update and reaffirmed guidance come after a period of strong share price momentum, with a 90 day share price return of...
NYSE:JBTM
NYSE:JBTMMachinery

JBT Marel (JBTM) Updated Guidance And Backed Buybacks, Is The Stock Cheap?

JBT Marel (JBTM) has drawn investor attention after its latest quarterly report, which paired updated 2026 revenue and earnings guidance with a new share repurchase program and a $0.10 quarterly cash dividend declaration. See our latest analysis for JBT Marel. Even with the stronger second quarter update and fresh capital return plans, JBT Marel’s recent momentum has been weak, with the share price down 14.01% over the last 30 days and 23.48% year to date. The 3 year total shareholder return...
NasdaqGM:LGND
NasdaqGM:LGNDPharmaceuticals

Reaffirmed 2026 Guidance After Strong Q2 Could Be A Game Changer For Ligand Pharmaceuticals (LGND)

In August 2026, Ligand Pharmaceuticals reported past second-quarter 2026 results showing revenue of US$63.69 million and net income of US$48.51 million, with basic earnings per share from continuing operations of US$2.42, alongside stronger first-half results than the prior year. Importantly for longer-term watchers, Ligand also reaffirmed its 2026 guidance for total revenue of US$270 million to US$310 million and GAAP net income of US$107 million to US$118 million, underscoring...
NasdaqGS:ILMN
NasdaqGS:ILMNLife Sciences

Did Illumina’s (ILMN) New Debt Deal and Credit Line Refresh Just Shift Its Investment Narrative?

In August 2026, Illumina, Inc. completed a US$299.913 million offering of 4.950% senior unsecured notes due September 19, 2029 and put in place a new US$1.00 billion unsecured revolving credit facility maturing in 2031, replacing its prior 2023 arrangement. Together, the fresh bond issuance and expanded revolving credit capacity indicate Illumina is actively reshaping its funding mix to support future corporate needs and balance-sheet flexibility. Next, we’ll examine how Illumina’s expanded...
NYSE:AFG
NYSE:AFGInsurance

American Financial Group (AFG) Back In Focus On Special Call As Valuation Gap Stays In View

Special call puts American Financial Group back under the microscope American Financial Group (AFG) has moved back into focus after its August 4 earnings release and a special call on August 13, which updated investors on recent performance and business trends. See our latest analysis for American Financial Group. Against this backdrop of the August earnings release and special call, American Financial Group’s recent share price has edged higher, with a 30 day share price return of 2.61%,...
NasdaqGS:TCBI
NasdaqGS:TCBIBanks

Is Texas Capital Bancshares (TCBI) Cheap As Texas ETFs Move To The Texas Stock Exchange?

Texas Capital Bancshares (TCBI) is in focus after Texas Capital Bank Private Wealth Advisors and Texas Capital Funds Trust moved to shift two Texas focused ETFs from the New York Stock Exchange to the new Texas Stock Exchange. See our latest analysis for Texas Capital Bancshares. At a share price of $99.83, Texas Capital Bancshares has seen some recent pressure, with the 1 month share price return down 4.99%. However, the year to date share price return of 8.87% and 1 year total shareholder...
NasdaqGS:PRGS
NasdaqGS:PRGSSoftware

Did Progress Software’s (PRGS) New CIO Mandate to Drive AI and Cybersecurity Just Shift Its Investment Narrative?

Earlier this week, Progress Software announced that Bridget Collins, a veteran technology leader with more than 30 years of enterprise IT, AI and cybersecurity experience, has been appointed Chief Information Officer reporting directly to CEO Yogesh Gupta to head its global IT and security organization. By giving Collins responsibility for advancing AI across internal operations, overseeing cybersecurity and supporting M&A integration, Progress is signaling a stronger emphasis on using...
NasdaqGS:AVAH
NasdaqGS:AVAHHealthcare

Aveanna Healthcare Holdings (AVAH) Is Up 41.6% After Raising 2026 Revenue Guidance Above US$2.68 Billion

Aveanna Healthcare Holdings Inc. recently reported past second-quarter 2026 results showing sales of US$670.48 million and net income of US$40.29 million, alongside modest impairment charges of US$145,000. Management also raised full-year revenue guidance to more than US$2.68 billion, signaling increased confidence in the company’s operating performance and demand backdrop. We’ll now examine how Aveanna’s raised full-year revenue guidance reshapes its existing investment narrative for...
NYSE:CRL
NYSE:CRLLife Sciences

Charles River Laboratories International (CRL) Cut 2026 Guidance, Is The Stock Still 11% Undervalued?

Charles River Laboratories International (CRL) cut its 2026 earnings guidance after reporting a second quarter net loss and slightly lower revenue. The company also continued its share repurchase program during the same period. See our latest analysis for Charles River Laboratories International. Despite the cut to 2026 earnings guidance and the recent quarterly net loss, Charles River Laboratories International’s share price has risen strongly over recent months, with a 30-day share price...
NYSE:BILL
NYSE:BILLSoftware

BILL Stock And 2 Digital Payments Picks Retail Investors May Want To Watch

AI is putting a fresh spotlight on who really profits from personal data, with proposals for $15,000 annual payments to families and talk of a $300b data market and trillion dollar AI IPOs. That debate could reshape how digital payments and benefits infrastructure businesses earn, tax and regulate revenue streams. This article looks at three US stocks exposed to that story and why their future cash flows may matter to your portfolio. The stocks highlighted below are just a sample, and the...
NYSEAM:UMAC
NYSEAM:UMACElectronic

Cerebras Stock And 2 Growth Picks for AI Infrastructure Investors

Global bond yields are pressing higher as markets react to stubborn inflation pressures from rising energy costs. That backdrop is punishing heavily indebted companies and rewarding businesses with cleaner balance sheets and clear earnings growth potential. The Healthy high growth potential screener filters for exactly that mix. This article highlights three stocks from the screener so you can see how this theme translates into real opportunities today. The three stocks below are just a small...
NasdaqGS:PRVA
NasdaqGS:PRVAHealthcare

Should Stronger 2026 Guidance and New Board Expertise Require Action From Privia Health Group (PRVA) Investors?

Privia Health Group, Inc. recently reported second-quarter 2026 results showing higher sales of US$632.63 million and improved profitability, and raised its full-year 2026 GAAP revenue outlook to the high end of its prior US$2.35 billion to US$2.45 billion range. The company also appointed experienced healthcare executive and physician Opella Ernest, M.D. to its Board and Compliance Committee, adding deep payer, clinical, and regulatory expertise that could be important as Privia scales its...
NYSE:ECL
NYSE:ECLChemicals

Raised 2026 Guidance and 89-Year Dividend Streak Could Be A Game Changer For Ecolab (ECL)

Ecolab’s board recently declared a regular quarterly cash dividend of US$0.73 per common share, payable on October 15, 2026, to shareholders of record on September 15, 2026, extending a cash dividend track record that now spans 89 consecutive years. This announcement comes as Ecolab highlights faster growth in its High-Tech, Digital and Life Sciences businesses and raises its 2026 adjusted earnings guidance, underscoring management’s focus on pricing, productivity and share gains even as...
NasdaqGS:DGII
NasdaqGS:DGIICommunications

Digi International (DGII) Earnings And Guidance Raise Fresh Questions About Valuation

Digi International (DGII) drew fresh investor attention after reporting third quarter fiscal 2026 results on 5 August, alongside updated guidance for the fourth quarter and full year revenue. See our latest analysis for Digi International. The earnings release and higher full year revenue guidance arrived after a strong run in Digi International’s stock, with a 30-day share price return of 26.78% and an 87.77% share price return year to date. Over the longer haul, total shareholder return of...
NasdaqGM:XENE
NasdaqGM:XENEBiotechs

Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?

Xenon Pharmaceuticals Inc. recently reported second-quarter 2026 results, with net loss rising to US$110.74 million and basic loss per share from continuing operations at US$1.11, alongside a six‑month net loss of US$213.04 million and basic loss per share of US$2.28. The widening losses compared with the same periods in 2025 give investors fresh insight into how Xenon is funding its ion-channel neurology pipeline ahead of key clinical and commercial milestones. We will now examine how...
NYSEAM:NHC
NYSEAM:NHCHealthcare

Why National HealthCare (NHC) Is Up 8.1% After Strong Q2 Earnings And Dividend Confirmation

National HealthCare Corporation recently reported past second-quarter 2026 results showing revenue of US$408.03 million and net income of US$40.32 million, alongside strong year-to-date earnings growth versus the prior year period. The company also confirmed it will pay a quarterly cash dividend of US$0.67 per common share to shareholders of record on September 30, 2026, reinforcing its focus on returning cash to investors. We’ll now look at how National HealthCare’s strong earnings growth...
NYSE:ZTO
NYSE:ZTOLogistics

How Stronger Earnings And Buybacks At ZTO Express (Cayman) (ZTO) Have Changed Its Investment Story

ZTO Express (Cayman) Inc. has reported past half‑year 2026 results showing CNY 27,832.26 million in sales and CNY 5,169.22 million in net income, alongside completing a US$138 million buyback of 6,161,216 shares representing 0.8% of its share count. The sharp uplift in both basic and diluted earnings per share from continuing operations highlights how recent operational performance and capital returns are reshaping the company’s financial profile. We’ll now examine how this earnings...
NasdaqGS:FIVE
NasdaqGS:FIVESpecialty Retail

Five Below (FIVE), What Is Behind The Fresh Attention?

Recent store openings and product launches are back in focus for Five Below (FIVE) after new locations in Sioux Falls and Poughkeepsie, alongside a fresh fall room decor range targeting value focused shoppers. See our latest analysis for Five Below. Recent openings like Sioux Falls and Poughkeepsie, along with the new fall room decor line, have coincided with stronger momentum for Five Below, with a 30 day share price return of 17.71% and a 1 year total shareholder return of 68.58%. If these...
NasdaqGS:RPRX
NasdaqGS:RPRXPharmaceuticals

How Investors Are Reacting To Royalty Pharma (RPRX) Buying Rusfertide Royalties From Zealand Pharma

In August 2026, Royalty Pharma plc agreed to provide US$100 million in funding to Zealand Pharma A/S in return for Zealand’s economic interests in rusfertide (PTG-300), including a 1% royalty on potential future global net sales and associated milestone payments, with payments split between closing and the first anniversary. This deal gives Royalty Pharma exposure to a potential first-in-class therapy for polycythemia vera while leaving Zealand Pharma with a smaller upside royalty on very...
NYSE:GEV
NYSE:GEVElectrical

Nuclear Energy Stocks For AI Power Demand Starting With NuScale Power Stock

Government bond yields in major markets are climbing as investors reassess long term inflation risks tied to higher energy costs. That shift keeps attention on power sources that do not rely on fossil fuel supply chains, including nuclear energy stocks. For investors, this creates a clear theme to explore. This article highlights 3 stocks from our Nuclear Energy Stocks screener that help you research this opportunity. The nuclear energy stocks in this article are only a starting sample, as...
NYSE:HSY
NYSE:HSYFood

Hershey (HSY) Expands Halloween Range As A Pricey Valuation Debate Builds

Hershey (HSY) is rolling out its largest Halloween portfolio to date, with more than 20 new products across chocolate, fruity candy and salty snacks, aimed at capturing broader seasonal snacking demand. See our latest analysis for Hershey. Against the backdrop of this expanded Halloween push, Hershey’s 1 month share price return of 7.02% contrasts with a 3 month share price decline of 3.87%. The 1 year total shareholder return of 4.54% sits alongside a 3 year total shareholder return decline...
NYSE:JPM
NYSE:JPMBanks

Does JPMorgan’s Upscale Chicago Flagship Reveal a Deeper Shift in Its Fee Model Strategy (JPM)?

In August 2026, JPMorgan Chase opened an 11,765 square foot two-story flagship at 830 N. Michigan Avenue in Chicago, combining a modern Chase branch with the city’s first co-located J.P. Morgan Financial Center offering everyday banking, lending, and personalized wealth services for affluent clients. This flagship, launched alongside an acceleration in branch openings and renovations nationwide, underlines JPMorgan’s push to blend physical presence with higher-touch advisory services as it...
NasdaqGS:EVCM
NasdaqGS:EVCMSoftware

Will CEO Transition and Lower-End 2026 Guidance Change EverCommerce's (EVCM) Vertical SaaS Narrative?

EverCommerce Inc. reported second-quarter 2026 results showing year-over-year increases in revenue to US$152.02 million and net income to US$9.72 million, while also issuing third-quarter revenue guidance of US$151.5 million to US$154.5 million and indicating full-year 2026 revenue is likely to land near the lower end of its US$612 million to US$632 million range. The company also completed a leadership transition, with founder Eric Remer stepping down as CEO and Chairman and long-time...